scholarly journals The Chronic Liver Diseases from Autoimmune cause, Autoimmune Hepatitis (AIH): Updating Review

2020 ◽  
Vol 7 (2) ◽  
pp. 1-17
Author(s):  
Baydaa Hameed Abdullah ◽  
Huda Jaber Waheed ◽  
Zahraa A.E Alnaqqash
Keyword(s):  
Immune Response ◽  
Liver Disease ◽  
Autoimmune Hepatitis ◽  
Liver Diseases ◽  
Pathological Condition ◽  
Acute Infection ◽  
Liver Cells ◽  
The Body ◽  
Chronic Liver ◽  
Biliary Cirrhosis

The classic autoimmune liver diseases (AILDs) are one of the main causes of chronic liver disease; which include primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) constitute and primary sclerosing cholangitis (PSC).This pathological condition represents an immune attack on the bile epithelial liver cells, which leads to chronic inflammation in the liver, due to the proliferation of cells and the deposition of the matrix proteins between the hepatocytes and their types. Then the liver cells gradually lose their functions until the liver reaches the stage of myofibroblasts.The liver lost its functions inevitably and gradually gets until the liver loses its normal size leads to high blood pressure in the hepatic portal vein and from here begins the rapid deterioration of the liver condition so this requires follow-up and monitoring of liver cirrhosis and at this stage requires a liver biopsy examination In this case, liver transplantation is the effective and golden treatment option for liver disease at this stage. The abundance of MHC receptors class II in the surface liver cells, genetic predisposition or due to acute infection of the liver, leads to an immune response in the body, which leads to autoimmune hepatitis. This abnormal immune response leads to persistent hepatitis, which may lead to more symptoms and complications such as fatigue and cirrhosis. The disease may be related to race or age, diagnosis is often after the age of 40 years.

scholarly journals The Chronic Liver Diseases from Autoimmune cause, Autoimmune Hepatitis (AIH): Updating Review

2020 ◽  
Vol 7 (2) ◽  
pp. 12-17
Author(s):  
Baydaa H. Abdullah ◽  
Huda J. Waheed ◽  
Zahraa A.E Alnaqqash
Keyword(s):  
Immune Response ◽  
Liver Disease ◽  
Autoimmune Hepatitis ◽  
Liver Diseases ◽  
Pathological Condition ◽  
Acute Infection ◽  
Liver Cells ◽  
The Body ◽  
Chronic Liver ◽  
Biliary Cirrhosis

The classic autoimmune liver diseases (AILDs) are one of the main causes of chronic liver disease; which include primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) constitute and primary sclerosing cholangitis (PSC).This pathological condition represents an immune attack on the bile epithelial liver cells, which leads to chronic inflammation in the liver, due to the proliferation of cells and the deposition of the matrix proteins between the hepatocytes and their types. Then the liver cells gradually lose their functions until the liver reaches the stage of myofibroblasts.The liver lost its functions inevitably and gradually gets until the liver loses its normal size leads to high blood pressure in the hepatic portal vein and from here begins the rapid deterioration of the liver condition so this requires follow-up and monitoring of liver cirrhosis and at this stage requires a liver biopsy examination In this case, liver transplantation is the effective and golden treatment option for liver disease at this stage. The abundance of MHC receptors class II in the surface liver cells, genetic predisposition or due to acute infection of the liver, leads to an immune response in the body, which leads to autoimmune hepatitis. This abnormal immune response leads to persistent hepatitis, which may lead to more symptoms and complications such as fatigue and cirrhosis. The disease may be related to race or age, diagnosis is often after the age of 40 years.

Autoimmunity in liver disease

2019 ◽  
pp. 245-252
Author(s):  
Gavin Spickett
Keyword(s):  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Autoimmune Hepatitis ◽  
Primary Sclerosing Cholangitis ◽  
Liver Diseases ◽  
Sclerosing Cholangitis ◽  
Biliary Cirrhosis

This chapter covers the presentation, immunogenetics, immunopathology, diagnosis, treatment, and testing for a range of liver diseases. Primary biliary cirrhosis, autoimmune hepatitis, and primary sclerosing cholangitis are described.

scholarly journals Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies

2016 ◽  
Vol 89 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Olga Hilda Orasan ◽  
George Ciulei ◽  
Angela Cozma ◽  
Madalina Sava ◽  
Dan Lucian Dumitrascu
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Diseases ◽  
Hereditary Hemochromatosis ◽  
Public Health Problem ◽  
Chronic Viral Hepatitis ◽  
Chronic Liver ◽  
Biliary Cirrhosis ◽  
Chronic Liver Diseases ◽  
Alcoholic Fatty Liver

Chronic liver diseases represent a significant public health problem worldwide. The degree of liver fibrosis secondary to these diseases is important, because it is the main predictor of their evolution and prognosis.Hyaluronic acid is studied as a non-invasive marker of liver fibrosis in chronic liver diseases, in an attempt to avoid the complications of liver puncture biopsy, considered the gold standard in the evaluation of fibrosis. We review the advantages and limitations of hyaluronc acid, a biomarker, used to manage patients with chronic viral hepatitis B or C infection, non-alcoholic fatty liver disease, HIV-HCV coinfection, alcoholic liver disease, primary biliary cirrhosis, biliary atresia, hereditary hemochromatosis and cystic fibrosis. 

scholarly journals The Role of the Gut Microbiome in Liver Cirrhosis Treatment

2020 ◽  
Vol 22 (1) ◽  
pp. 199
Author(s):  
Na Young Lee ◽  
Ki Tae Suk
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Gut Microbiota ◽  
Gut Microbiome ◽  
Liver Diseases ◽  
Sclerosing Cholangitis ◽  
Chronic Liver ◽  
Chronic Liver Diseases

Liver cirrhosis is one of the most prevalent chronic liver diseases worldwide. In addition to viral hepatitis, diseases such as steatohepatitis, autoimmune hepatitis, sclerosing cholangitis and Wilson’s disease can also lead to cirrhosis. Moreover, alcohol can cause cirrhosis on its own and exacerbate chronic liver disease of other causes. The treatment of cirrhosis can be divided into addressing the cause of cirrhosis and reversing liver fibrosis. To this date, there is still no clear consensus on the treatment of cirrhosis. Recently, there has been a lot of interest in potential treatments that modulate the gut microbiota and gut-liver axis for the treatment of cirrhosis. According to recent studies, modulation of the gut microbiome by probiotics ameliorates the progression of liver disease. The precise mechanism for relieving cirrhosis via gut microbial modulation has not been identified. This paper summarizes the role and effects of the gut microbiome in cirrhosis based on experimental and clinical studies on absorbable antibiotics, probiotics, prebiotics, and synbiotics. Moreover, it provides evidence of a relationship between the gut microbiome and liver fibrosis.

Primary Biliary Cirrhosis

2015 ◽  
Author(s):  
Daniel S. Pratt ◽  
Lindsay Y. King
Keyword(s):  
Differential Diagnosis ◽  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Liver Diseases ◽  
American Association ◽  
Cholestatic Liver Disease ◽  
Biliary Cirrhosis ◽  
Common Cause ◽  
History Of

Primary biliary cirrhosis (PBC) is a progressive autoimmune disease of the liver. It is the most common cause of chronic intrahepatic cholestatic liver disease in adults. This review addresses the epidemiology, etiology and genetics, pathophysiology and pathogenesis, diagnosis, differential diagnosis, treatment, complications, and prognosis of PBC. Figures show the pathogenesis and natural history of PBC and histologic features of the four stages of PBC. Tables list diagnostic criteria for PBC via the American Association for the Study of Liver Diseases, differential diagnosis for PBC, medications used to treat PBC, secondary therapy for PBC, and follow-up of patients with PBC. This review contains 2 highly rendered figures, 5 tables, and 45 references.

Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis

1996 ◽  
Vol 24 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Albert J. Czaja ◽  
Herschel A. Carpenter ◽  
Paula J. Santrach ◽  
S. Breanndan Moore
Keyword(s):  
Autoimmune Hepatitis ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases

scholarly journals Correlation Between Body Composition Analysis and Biochemical Nutritional Markers in Maintenance Hemodialysis Patients with Chronic Liver Disease

2020 ◽  
Vol 71 (11) ◽  
pp. 94-100
Author(s):  
Luciana Carmen Nitoi ◽  
Valeriu Ardeleanu ◽  
Anca Pantea Stoian ◽  
Lavinia Alexandra Moroianu
Keyword(s):  
Body Composition ◽  
Liver Disease ◽  
Nutritional Status ◽  
Chronic Liver Disease ◽  
The Body ◽  
Chronic Liver ◽  
Composition Analysis ◽  
Arterial Line ◽  
Body Protein ◽  
Total Body

Several approaches have been used to assess protein-energy wasting syndrome, such as clinical evaluation, biochemical nutritional markers, anthropometric measurements, but Bioelectrical Impedance Analysis (BIA) techniques hold a central place in clinical settings. The aim of this study is to report our clinical experience with BIA and the correlations between biochemical nutritional markers and BIA nutritional parameters in hemodialysis (HD) patients associating or free of chronic liver disease. This cross-sectional observational study included 69 HD patients divided into two groups: 33 with chronic liver disease (CLD+) versus 36 chronic liver disease-free (CLD-) from one HD unit in Romania. Serum albumin (SA), serum creatinine (SCr) and C-reactive protein (CRP) were obtained from the HD arterial line immediately before the HD session and by BIA the body composition including total body water (TBW), total body fat (TBF), lean fat free mass(LFFM), body muscular mass (BMM), malnutrition index and body protein reserve (PR) were assessed. No significant differences between groups were found in BCM, BMM, PR and TBF (p = 0.92, p = 0.60, p = 0.907, and p = 0.634, respectively). Malnutrition index had a significantly higher mean value in HD-CLD(+) patients (p = 0.00). HD-CLD(-) group showed a strong correlation between SA and SCr and BCM, BMM (kg), LFFM (kg) and body PR (kg) (r=.48, r=.50, r=.44, r=.50; resp. r=.42, r=.40, r=.36, r=.42). In HD-CLD(+) patients, a significant positive correlation was found between SA and SCr and LFFM and body PR (r=.37, r=.35; resp. r=.44, r=.35). Discussion: BIA is one of the most accurate techniques for assessing nutritional status and should be regularly used in clinical practice along with biochemical nutritional markers in HD patients. Although the protein metabolism depends to a large extent on liver function, CLD cannot be considered as having a significant impact on nutritional status in HD patients.

scholarly journals Imaging Software-Based Sarcopenia Assessment in Gastroenterology: Evolution and Clinical Meaning

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Giovanni Marasco ◽  
Sinan Sadalla ◽  
Giulio Vara ◽  
Rita Golfieri ◽  
Davide Festi ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Liver Disease ◽  
Liver Failure ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Failure ◽  
Cross Sectional ◽  
Cross Sectional Imaging ◽  
Sectional Imaging

Sarcopenia is gaining attention as a negative prognostic factor in different fields of medicine, including chronic liver failure. However, the assessment of sarcopenia in patients with liver diseases is often neglected due to unawareness of reliable tools and methods and thus is limited to research studies. Cross-sectional imaging is a diffuse diagnostic tool and is commonly performed in patients with chronic liver failure. The last advancements in radiology image analysis using dedicated software allow an easy and standardized method to assess skeletal muscle volume. Several measures can be obtained from cross-sectional imaging analysis to evaluate sarcopenia in patients affected by chronic liver disease. We aimed to review the recent advances in imaging-based sarcopenia assessment, in particular in patients with chronic liver diseases. As a result, we found that the skeletal muscle index (SMI) seems to be a reliable method to assess sarcopenia in cirrhotic patients. Even if further studies are needed to validate proper cut-offs for each clinical endpoint, physicians are invited to consider the assessment of sarcopenia in the work-up of patients with chronic liver disease.

scholarly journals Asthenia and fatigue in hyperammonemia: etiopathogenesis and methods of correction

2022 ◽  
pp. 95-104
Author(s):  
E. Yu. Plotnikova ◽  
M. N. Sinkova ◽  
L. K. Isakov
Keyword(s):  
Liver Disease ◽  
Liver Diseases ◽  
Signs And Symptoms ◽  
Chronic Liver ◽  
Blood Levels ◽  
Chronic Liver Diseases ◽  
Life Threatening ◽  
Underlying Causes ◽  
Principles Of Treatment ◽  
The Brain

Asthenia and fatigue are the most common syndromes in patients with liver disease, which significantly affects their quality of life. The prevalence of fatigue in chronic liver diseases is from 50% to 85%. While some progress has been made in understanding the processes that can cause fatigue in general, the underlying causes of fatigue associated with liver disease remain not well understood. In particular, many data suggest that fatigue associated with liver disease likely results from changes in neurotransmission in the brain against the background of hyperammonemia. Hyperammonemia is a metabolic state characterized by an increased level of  ammonia, a  nitrogen-containing compound. The  present review describes hyperammonemia, which is likely important in the pathogenesis of fatigue associated with liver disease. Ammonia is a potent neurotoxin, its elevated blood levels can cause neurological signs and symptoms that can be acute or chronic, depending on the  underlying pathology. Hyperammonemia should be recognized early, and immediately treated to prevent the development of life-threatening complications, such as, swelling of the brain and coma. The article gives pathophysiological mechanisms of influence of hyperammonemia on state of psychovegetative status of patients with liver diseases, also lists basic principles of treatment. A significant part of the article is devoted to L-ornithine-L-aspartate, which is effective in asthenia and fatigue to reduce the level of hyperammonemia through a variety of well-studied mechanisms in chronic liver diseases.

Sign in / Sign up

Export Citation Format

Share Document